A Gutsy Combination: The Microbiome and Immuno-oncology
As science explores the microbiome’s effects on the immune system and its role in treating cancer, drug developers are investing substantially to capitalize on findings connecting the microbiome, immunology, and oncology.
For our latest white paper, Back Bay Life Science Advisors analyzed the activity of drug developers looking to harness microbial pathways to improve cancer treatment; the current drug pipeline; active clinical trials; and evolving regulatory and IP issues for the development of these technologies.
As rates of epilepsy continue to climb, drug developers have cut back in research in this area, many are deterred by the large number of existing drugs and off-patent drugs on the market, the challenge of large clinical trials and unclear financial rewards.
Immuno-oncology, a promise for decades, has burst forth as a clear means to advance patient care and spur research and development. Science and industry are working fervently to untangle this data-heavy, rapidly-evolving field and bring effective IO combinations to more patients. As positive data and widespread support accumulate for the potential checkpoint inhibitors and neoantigens in numerous challenging and refractory cancers, hundreds of trials are being implemented that seek to increase efficacy and bring these novel therapeutics to more patients in critical need.
By Tejdeep Singh Bawa, Michelle Hoffmann, Susan Thompson, Stephanie Kwei
Medical device companies developing next-generation mitral valve repair and replacement technologies have generated unprecedentedly high valuations at ever-earlier stages of device development. Medtech investors are acquiring early-stage transcatheter mitral valve technologies long before commercialization and even before critical clinical data is amassed.